Kornimate/medical-research-clean huggingface dataset:
pediatric pertussis in ambulatory settings

Conditions: Pertussis/Whooping Cough; Children, Only; Ambulatory

Summary: since 2002, whooping cough surveillance in pediatric private practice has been set up in france. the results of the first years, 2002-2006, have confirmed the effectiveness of the pertussis whole-cell (pw) vaccine and in particular the duration of protection of 9/10 years. after evaluating cases in children vaccinated with pw vaccines, the study aims today to analyze cases in children vaccinated with pertussis acellular (pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in france (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).

the whooping cough surveillance objectives are : * to follow the duration of protection of the ca vaccines in the context of modifications of the vaccine recommendations * to describe the clinical characteristics of a population vaccinated with several boosters * to adapt complementary examinations for diagnostic purposes (culture, pcr, serology) according to the evolution of scientific knowledge * to monitor b. parapertussis infections * to train laboratories with nasopharyngeal aspiration * to monitor the evolution of the bacterial species all children aged 0-18 years, in whom the diagnosis of pertussis is mentioned and for which a biological check-up is requested, are included, except asymptomatic children with confirmed family case. in case of suspected pertussis, real-time pcr and / or culture and / or (rarely) serology is / are still prescribed to the patient and / or his entourage. selected pediatricians from the activ group and the afpa working in an outpatient clinic, located in different places in france, are participating in this network since 2001. the clinical evolution and the results of the examinations are transcribed on a case report form. the data are collected, firstly, during the visit where the diagnosis of whooping cough is suspected and a biological assessment requested (patient's medical history, clinical data, vaccination status and dates, as well as the search for a contaminated/contaminator) and secondly during the follow-up visit (results of the biological check-up and diagnosis, antibiotics potentially prescribed, and supplement data of the entourage, except in case of diagnosis of pertussis not retained). all evaluations made by the pediatricians are regularly reviewed during meetings, and final diagnoses used are: * biological pertussis * epidemiological pertussis * not evaluable * lost of follow up * no whooping cough

Eligibility criteria:
inclusion criteria: * all children under 18 years old with a pertussis diagnosis is suspected and a biological exam is requested exclusion criteria: * children without symptoms with a household confirmed case * cases for which the pertussis diagnosis was not suspected by the pediatrician

Keywords: pertussis surveillance pertussis acellular vaccine
comparative study on the efficacy of olinano seal and curodont d' senz in treatment of dentin hypersensitivity

Conditions: Dentin Hypersensitivity

Summary: this study was conducted to evaluate and compare the efficacy of olinanoseal and curodont d'senz in treatment of dentin hypersensitivity.

materials and methods:- a total of ninety (90) samples were used in the study, for dentin permeability test (dye penetration test) and scanning electron microscopic examination (sem) which were randomly divided into two main groups; group a1, completely removed smear layer, group a2, partially removed smear layer. each group was subdivided into three subgroups according to the desensitizing agent applied: olinano seal, curodont d'senz and the control group that were left untreated. seventy (70) hypersensitive teeth in ten patients were enrolled for the current study. the subjective assessment of dentin hypersensitivity was done prior to the application of the desensitizing agent (baseline) then immediately, 2 weeks, 4 weeks and 3 months after application of the tested materials. patients were informed to rate their perception to tactile, air and cold stimuli by using verbal rating score (vrs) and visual analogue scale (vas).

Eligibility criteria:
inclusion criteria: 1. presence of a minimum of four hypersensitive teeth in each patient. 2. patients with teeth recorded a discomfort score of two or more to tactile, cold and air stimulation. 3. teeth having hypersensitivity only on the facial aspect. 4. patients' willingness to participate in the study exclusion criteria: 1. patients with any medical or dental condition that could impact the study results during its expected length. 2. patients with a history of drug addictions and use of potent analgesic and/ or anti-inflammatory drugs. 3. patients who refused to give their consents. 4. patients with any extensive or unsatisfactory restorations, prosthesis or orthodontic appliances which involve the cervical areas

Keywords: olinano seal curodont d'senz dentin hypersensitivity dye penetration dentin permeability
mri to measure liver fat content

Conditions: Fatty Liver; Hepatitis

Summary: this study will determine whether a magnetic resonance imaging (mri) test of the liver can accurately measure the amount of fat in the liver compared to the results of a liver biopsy. people 18 years of age and older who are scheduled to have or who have already had a liver biopsy as part of their medical care within 1 month of enrollment in this study may be eligible to participate. participants undergo an mri. for this procedure, the subject lies still on a table that slides into a narrow metal cylinder (the mri scanner) for 30 to 60 minutes. a special pad or tube is placed around the abdomen to improve the image of the liver obtained. earplugs are placed in the ears to muffle loud thumping and knocking sounds that occur with the electrical switching of the magnetic field. the findings of the mri are compared with those of the liver biopsy.

percutaneous liver biopsy remains the gold standard test to evaluate hepatic fat content, fibrosis and cirrhosis, but there is growing interest in the application of magnetic resonance imaging (mri) techniques such as (1)h-magnetic resonance spectroscopy ((1)h-mrs) as a non-invasive approach to quantify these characteristics. the ability to accurately quantify hepatic metabolites, such as intrahepatic lipid, has important implications for clinical evaluation and management of patients with liver related diseases and may obviate the need for liver biopsies in a number of clinical settings. the current proposal is designed to develop and validate hepatic (1)h-mrs capabilities at the nih clinical center and to use this technique in a subsequent study to estimate the prevalence of hepatic steatosis among persons living with hiv/aids. in the present study we propose to complete mri with (1)h-mrs in 70 adults who will be undergoing percutaneous liver biopsy in order to establish the ability of (1)h-mrs to accurately assess hepatic fat content compared to histopathological scoring.

Eligibility criteria:
* inclusion criteria: age 18+, male or female planned liver biopsy or liver biopsy within the past month with pathology samples available to be read at nih cc exclusion criteria: known current pregnancy or pregnancy within 6 months contraindications to mri subject is deemed unable to comply with requirements of study participation

Keywords: 1h-magnetic resonance spectroscopy hepatic steatosis liver fat liver biopsy liver hepatitis fatty liver
laser speckle contrast imaging for cutaneous microvascular dysfunction detection in systemic sclerosis.

Conditions: Raynaud Disease; Scleroderma, Systemic

Summary: the aim of the study is to determine if postocclusive hyperemia of palmar and dorsal face of the hand with laser speckle contrast imaging discriminate between patients with systemic sclerosis, subjects with primary raynaud's phenomenon and healthy subjects.

microvascular dysfunction is a key event in the pathogenesis of systemic sclerosis. there are currently no test measuring it in clinical practice. response to humeral occlusion is interesting and this response has been studied with laser doppler flowmetry. more recently, laser imaging has been used analysing the granularity of the laser: laser speckle contrast imaging which allow combining high temporal resolution to high spatial resolution. the investigators proposed, in this study, to compare this imaging at basal and after post-occlusive hyperaemia of dorsal and palmar face of hand in 3 groups: healthy subjects, primary raynaud's phenomenon and systemic sclerosis.

Eligibility criteria:
inclusion criteria: * healthy subjects: * man ou woman 18 years old or more. * without raynaud's phenomenon or systemic sclerosis. raynaud's phenomenon subjects: * man ou woman 18 years old or more. * with primary raynaud's phenomenon. systemic sclerosis: * man ou woman 18 years old or more. * systemic sclerosis in accordance to leroy's classification. exclusion criteria: * active digital ulceration * bosentan, iloprost ou sildenafil treatment * history of axillary dissection , trauma or surgery * history of thromboembolic disease or thrombophilia * minor or law-protected major * exclusion period in another study * no affiliation to medicare * pregnant, parturient or breasting woman * concomitant serious disease: progressive cancer, liver failure, history of myocardial infarction less than 5 years, angor * smoking in the 6 last months * person deprived of liberty by a legal or administrative decision, person under legal protection * maximal annual indemnification reached.

Keywords: healthy subject hand blood flow laser speckle contrast imaging
ramucirumab use in combination with paclitaxel in gastric or gastroesophageal junction adenocarcinoma; temporary authorization for use (atu) in france

Conditions: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma

Summary: the treating physician/investigator contacts lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the atu.


Eligibility criteria:
inclusion criteria: * the participant has histologically or cytologically confirmed gastric adenocarcinoma, including gastroesophageal junction (gej) adenocarcinoma (participants with adenocarcinoma of the distal esophagus are eligible if the primary tumor involves the gej.) after prior chemotherapy. * acceptable prior chemotherapy regimens for this protocol are combination chemotherapy regimens that include platinum or fluoropyrimidine components (acceptable prior platinum agents are cisplatin, carboplatin, or oxaliplatin; acceptable prior fluoropyrimidine agents are 5-fluorouracil (5-fu) and capecitabine). prior trastuzumab use in human epidermal growth factor receptor 2 positive (her2+) participants is accepted too. * the participant is eligible for treatment by chemotherapy and has an eastern cooperative oncology group performance status (ecog ps) score of 0 or 1. exclusion criteria: * participant has a known allergy to any of the treatment components.
aerofit post market investigation

Conditions: Transfemoral Amputation; Amputation; Skin Health

Summary: the goal of this clinical investigation is to evaluate the clinical benefits of a ventilating suspension interface for individuals with transfemoral amputation. the main aim of the investigation will be to evaluate the clinical user-reported benefits to skin health from using a ventilating lower limb prosthetic suspension system and compare it to a non-ventilating suspension system.


Eligibility criteria:
inclusion criteria: * 50kg\< body weight \< 136kg * cognitive ability to understand all instructions and questionnaires in the study * intended for unilateral/bilateral individuals that fit the indications for use, fit within the specified criteria and with the limb length, shape and ability to use a prosthetic liner: activity level: k1 - k4, impact level: low to high, amputation level: transfemoral * congenital transverse deficiency at femoral level * using seal-in silicone liner and direct socket or aerofit seal-in liner and aerofit socket * able to use aerofit solution, see figure 7 aerofit seal-in liner sizes and figure 8 minimum socket height per liner profile. * residual limb profile: standard or conical * willing and able to participate in the study and follow the protocol * confident (all day) prosthetic users for more than 3 months * older than 18 years exclusion criteria: * participating in another research study that may affect the participation or results of this study (in the opinion of the investigator) * users that have received botox injection as treatment for residual limb sweat issue in the last 4 months
clinical study on the application of a non-invasive micro-focused ultrasound with visualization system for skin laxity (ult-215)

Conditions: Facial Skin Laxity

Summary: to evaluate the effect of the ulthera® system for facial laxity and sagging skin


Eligibility criteria:
inclusion criteria: 1. willing to sign a written consent form 2. willing to have of facial skin laxity and wrinkles assessed by clinician 3. male or female, aged 39 to 65 years. 4. willingness to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study. 5. willingness to cooperate with photography and adherence to photography procedures (i.e., removal of jewelry and makeup). 6. must understand the ultrasound device (ulthera) treatment may have no therapeutic effect. 7. willingness and ability to provide written informed consent and hipaa authorization prior to performance of any study-related procedure. exclusion criteria: 1. open wounds or lesions in the area(s) to be treated. 2. severe or cystic acne on the area(s) to be treated. 3. presence of an active systemic or local skin disease that may affect wound healing. 4. active implants (e.g., pacemakers or defibrillators), or metallic implants in the treatment areas (dental implants not included.). 5. subcutaneous fillers 6. keloid scar 7. patients with anticoagulant treatment plan. 8. children, pregnant women, breastfeeding women. 9. patients with the following disease conditions: bleeding disorders or coagulation disorder that may affect wound healing, active localized disease, herpes simplex, autoimmune diseases, diabetes, epilepsy bell-type paralysis (temporary facial palsy)
serratus anterior block and catheter use in rib fractures in the emergency department

Conditions: Anesthesia; Rib Fractures

Summary: the main aim of this study is to determine whether serratus anterior plane (sap) blockade provides improved pain relief after rib fractures compared to epidural administration of local anaesthetic. the investigators aim to show that sap catheters (sapc) can be placed in more situations and are less operator-dependent then thoracic epidural anaesthesia (tea). this reduces the waiting time required to achieve satisfactory analgesia in the patient. optimal analgesia allows early respiratory physiotherapy and reduction in the complications of multiple rib fractures. pain from rib fractures is severe. the sensory nerves of the thoracic wall lie in the sap and a single ultrasound-guided injection of local anaesthetic spreads widely and provides useful post-injury analgesia for several hours. if a catheter is left in the sap, the nerve blockade can be maintained for several days. rib fracture pain is traditionally treated with oral/ intravenous analgesics or tea. opiate analgesia via patient controlled analgesia (pca) can work very well but it is associated with excessive sedation, constipation, nausea and vomiting. continuous tea is generally regarded as the gold standard but it demands monitoring by adequately trained ward staff and is commonly associated with high failure rates and increased risk of complications. sapc has also been used when tea and pca were not desirable. the primary outcome will be the amount of morphine analgesia required by the patient. secondary outcomes will be pain scores (at rest and on movement), the side effects of morphine, complications of tea/ sapc, respiratory function changes and a quality of recovery assessment. the control group will have an epidural block and catheter placed. the treatment group will have sap blocks and catheters placed under ultrasound guidance. both blocks will be tested to ensure good pain relief. to avoid potential confounding effects, oral painkillers will adhere strictly to the study protocol.


Eligibility criteria:
inclusion criteria: * patients aged over 18 years suffering 2 or more rib fractures exclusion criteria: 1. significant renal dysfunction (baseline creatinine \>150μmol/l - morphine contra- indicated) 2. pregnancy 3. patients with chronic pain on regular analgesic medication 4. patients with significant coagulation abnormality (unsafe to site blocks) 5. participation in another interventional study that will interact with this trial. 6. patients unable to give informed consent 7. hypersensitivity to local anaesthetic (or any other study drug). 8. contraindication to nsaid (peptic ulceration or sensitive asthma) 9. weight \<50kg

Keywords: regional anaesthesia rib fractures
evaluation of clinical outcomes of pulse widths in spinal cord stimulation

Conditions: Back Pain; Pain

Summary: the purpose of this study is to evaluate the effect of pulse widths \ 1000 μsec on clinical outcomes during a temporary scs trial.

the proposed study is a prospective, multi-center, two-arm, randomized, crossover design to be conducted at up to 10 sites. the study will enroll up to 100 subjects in order to include up to 10 subjects in the study per site. subjects selected to participate in the trial have back and/or leg pain, have been evaluated as a candidate for scs and have agreed to undergo a temporary scs trial using the algovita® system with percutaneous leads. each subject will be followed during the trial period of approximately 7+/-2 days. the study will end when the last subject has completed the trial period and exited. the expected enrollment period for this study is approximately six months. after exit from the clinical study, subjects will continue to be followed by their physician per usual care. all device and procedure-related aes will be collected and reported per the study protocol.

Eligibility criteria:
inclusion criteria: * be eligible for scs therapy according to the algovita® scs system indications for use statement * be undergoing a scs trial using algovita® scs system * sign a valid, institutional review board (irb)-approved informed consent form. * be 18 years of age or older when written informed consent is obtained exclusion criteria: * be contraindicated for an algovita® scs system * have a cognitive impairment or exhibits any characteristic, that would limit the study candidate's ability to assess pain relief or complete study assessments * have a life expectancy of less than 2 years * be participating in another clinical study that would confound data analysis * have a coexisting pain condition that might confound pain ratings * have a significant psychiatric disorder
efficacy and safety of low-dose conbercept for retinopathy of prematurity therapy

Conditions: Retinopathy of Prematurity (ROP)

Summary: evaluating the optimal effective dose and safety of conbercept in treating retinopathy of prematurity (rop)


Eligibility criteria:
inclusion criteria: * preterm infants with less than or equal to 2000 grams of birth weight or less than or equal to 32 weeks of gestational age * bilateral type 1 rop with one of the following retinal findings in each eye * zone i, stage 1+, 2+, 3+/- disease, or * zone ii, stage 2+, 3+, disease, or * a-rop exclusion criteria: * preterm infants with stage 4 or 5 rop in one or both eyes * have received any previous surgical or nonsurgical treatment for rop, including laser photocoagulation, anti-vegf therapy, vitrectomy * have been previously exposed to any intravitreal or systemic anti-vegf agent (either the patient or the mother during this child's pregnancy) * have used (either the patient or the mother) other investigational drugs as part of another clinical study (other than vitamins and minerals) within 30 days or within 5 half-lives of the other investigational drug, whichever is longer * have active ocular infection within 5 days before or on the day of first investigational treatment * have a history of hypersensitivity (either the patient or the mother) to any of the investigational treatments or to drugs of similar chemical classes * have any contraindication for intravitreal injection clearly stated in the instructions * have any ocular structural abnormality that may affect efficacy assessments * have a history of any other congenital or systemic conditions that are assessed by the investigator to have a significant risk of severe impact on visual function * have any other medical conditions or clinically significant comorbidities or personal circumstances that are assessed by the investigator to have a clinically relevant impact on study participation, any of the study procedures, or on efficacy assessments
everolimus and temozolomide in advanced gastroenteropancreatic neuroendocrine carcinoma (g3)

Conditions: Neuroendocrine Carcinoma

Summary: to study the efficacy of everolimus combined with temozolomide as first-line treatment in advanced gastroenteropancreatic neuroendocrine carcinoma with a ki67 of 20-55%, measured as disease control rate (non-progressive disease) at 6 months.

guidelines for treating advanced gastroenteropancreatic neuroendocrine carcinomas (gep-necs) advocate the use of combination chemotherapy with a platinum-based chemotherapy combined with etoposide. no other regimen has consistently shown a benefit over this combination. necs do not respond to treatments usually applied in other neuroendocrine tumours such as somatostatin analogues and interferon. in contrast to metastatic neuroendocrine tumours with a low ki67, debulking surgery and surgery for liver metastasis is generally not recommended. cisplatin /carboplatin and etoposide is established as standard treatment of advanced disease based on two small retrospective studies showing a response rate between 41- 67% and median survival of 15-19 months. in the current trial we propose an alternative treatment for a subgroup of patients with gep-nec based on new data, with the intention to improve response rates and clinical benefit rate without increasing toxicity

Eligibility criteria:
inclusion criteria histologically proven neuroendocrine carcinoma with a ki67 of 20-55%.primary gastroenteropancreatic tumor or cancer of unknown primary where metastases are mainly abdominalmeasurable disease according to recist by ct/mr general conditions: * \>18 years; * who/ecog performance status 0-1. * adequate haematological, renal and hepatic functions: * written informed consent prior to inclusion prior therapy: * no prior chemotherapy treatment for advanced disease. * adjuvant chemotherapy must have ended \> 6 months before inclusion. prior or current history: * no curatively resectable disease; * no other serious illness or medical conditions (including: unstable angina, myocardial infarction within 6 months, unstable diabetes, immune suppression ) concomitant treatments : * no concomitant (or within 4 weeks before inclusion) administration of any other experimental drug; * no other concurrent anti-cancer therapy. other : * not pregnant or breast feeding. fertile patients must use adequate contraceptives and fertile females must have a negative pregnancy test.

Keywords: gastroenteropancreatic neuroendocrine carcinoma chemotherapy